Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trichlormethiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichlormethiazide SCHEMBL25492 | 1.00 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL29356280 | 1.00 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| Teclothiazide SCHEMBL7621916 | 0.91 | LMNA (0.83) | LMNACA1CA2CA7HTT | |
| SCHEMBL30561865 | 0.88 | LMNA (0.79) | LMNACA1CA2CA7HTT | |
| SCHEMBL29132639 | 0.88 | LMNA (0.79) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL20775173 | 0.88 | LMNA (0.78) | LMNACA1CA2CA7HTT | |
| Cyclopenthiazide SCHEMBL13723122 | 0.85 | LMNA (0.85) | LMNACA1CA2CA7HTT | |
| Methyclothiazide SCHEMBL10380303 | 0.85 | CHRM1 (0.77) | LMNACA1CA2CA7HTT | |
| SCHEMBL17471573 | 0.84 | LMNA (0.72) | LMNACA1CA2CA7HTT | |
| Cyclothiazide SCHEMBL21587525 | 0.83 | LMNA (0.85) | LMNACA1CA2CA7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12536 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-12203941-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | ASTUTE MEDICAL, INC. (US) | 2025-01-21 | — | — | US | claimed |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-11-14 | — | — | US | claimed |
| US-12121509-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| EP-4400105-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | Shionogi & Co., Ltd (JP) | 2024-07-17 | — | — | EP | claimed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| US-4311697-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-19 | — | — | US | claimed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | claimed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | claimed |
| EP-0032564-A1 | Pharmaceutical use of caroverine and/or salts of caroverine, as well as salts of caroverine with xanthine acid remainders and nicotinic acid remainder | MEDICHEMIE AG (CH) | 1981-07-29 | — | — | EP | claimed |
| US-4265893-A | 2,4-DIAMINO-5-(4-AMINO-3,5-DIALKOXY BENZYL) PYRIMIDINE AS POTASSIUM RETAINING COMPOUND | HOFFMANN-LA ROCHE INC. (US) | 1981-05-05 | — | — | US | claimed |
| US-4238485-A | 1,2,5-THIADIAZOLE DERIVATIVE, THIAZIDE DIURETIC, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-12-09 | — | — | US | claimed |
| US-4217347-A | MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | claimed |
| EP-0008367-A1 | N-Arylsulfonyl pyrroles, their preparation and medicaments containing them | BASF Aktiengesellschaft (DE) | 1980-03-05 | — | — | EP | claimed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | claimed |